Riggs, Lace M. http://orcid.org/0000-0003-4368-4089
An, Xiaoxian http://orcid.org/0000-0002-1739-6342
Pereira, Edna F. R.
Gould, Todd D. http://orcid.org/0000-0003-1511-7183
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01-MH107615, R01-MH107615-03S2, R01-MH107615-04S1, F31-MH123066)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Veterans Affairs (BX003631, BX004062)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32-GM008181, R25-GM055036)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (T32-NS063391)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 22 June 2021
Revised: 21 September 2021
Accepted: 29 September 2021
First Online: 12 November 2021
Competing interests
: This research was supported by NIH/NIMH F31-MH123066 (to LMR), NIH/NIGMS T32-GM008181 (to LMR), NIH/NINDS T32-NS063391 (to LMR), NIH/NIGMS R25-GM055036 (to LMR), NIH/NIMH R01-MH107615 (to TDG), NIH/NIMH R01-MH107615-03S2 (TDG), R01-MH107615-04S1 (to TDG), and U.S. Department of Veterans Affairs Merit Awards BX003631 and BX004062 (to TDG). The contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. TDG has received research funding from Allergan and Roche Pharmaceuticals during the preceding 3 years and is a consultant for FSV7 LLC. TDG is listed as the inventor on a patent application for the use of (<i>2</i> <i>R,6</i> <i>R</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. TDG has assigned his patent rights to the University of Maryland, Baltimore, but will share a percentage of any royalties that may be received by the University of Maryland, Baltimore. LMR, XA, and EFRP declare no competing interests.